Posters on the topic "CGRP (receptor) inhibitors in the clinic"

Erenumab-treated patients and the risk of hypertension: a retrospective real-world study

Arthralgia: A potential side effect of CGRP inhibitors

Real-world insights into migraine associated with menstruation, prodrome, and aura: patient-reported outcomes of Gepant treatment in a tertiary care center

Patient characteristics and clinical response to Fremanezumab in Episodic cluster headache: insights into CGRP and PACAP pathways

A single-centre retrospective audit of prevalence of constipation as a side-effect of Erenumab (Aimovig) treatment in the management of refractory chronic migraine

Retrospective real-world study of Calcitonin Gene-related Peptide monoclonal antibody (CGRP mAb) for migraine in a Singapore neurology clinic

Constipation as an adverse effect of all the subcutaneous anti CGRP monoclonal antibodies: relation to pre-existing constipation and impact on migraine treatment

Calcitonin gene-related peptide monoclonal antibodies and concomitant autoimmune related disorders

Blood pressure in migraine patients undergoing treatment with CGRP monoclonal antibodies in patients with migraine – a systematic review and potential implications for clinical practice

Anti-CGRP monoclonal antibodies treatment discontinuation in migraine: when and why

Efficacy and safety of rimegepant for the preventive treatment of fasting-related headache during Ramadan in the UAE

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan

Efficacy and safety of rimegepant for the prevention of migraine in Japan

Consistency of effect of rimegepant as an acute treatment for migraine attacks: Data from a real-world survey

Cognitive improvement in a patient undergoing Eptinezumab for the treatment of chronic migraine – a case report

Real-world effectivenes and tolerability of switching between CGRP pathway tageting antibodies: Czech Migraine Registry (ReMig)

Fremanezumab for the treatment of migraine and medication overuse headache – a systematic review and meta-analysis

Effectiveness and safety of anti-CGRP treatment in migraine patients with autoimmune diseases: multicenter "ImmunoCGRP" case-control study

Eptinezumab treatment in patients with previous anti-CGRP(R) monoclonal antibodies therapy (mAbs) – a retrospective study of real-world clinical evidence of efficacy

Effectiveness and tolerability of lasmiditan in the acute migraine treatment (DART) – a real-world multicentric study

Evaluating safety, effectiveness, and impact on multiple sclerosis disease course of Anti-CGRP monoclonal antibodies combined with disease-modifying treatments – a multicentric study

A multidisciplinary multicentric approach to the identification of BIOmarkers of MIGraine (BIOMIGA project): an open-label, prospective biochemical study based on the stratification of responders to Erenumab

Effectiveness and tolerability of fremanezumab in real-world clinical practice:Results of the 24-month prospective observational study FINESSE

Real-world long-term effectiveness of fremanezumab in patients with migraine who switched from another mAb targeting the CGRP pathway – subgroup analysis of the FINESSE full analysis

Lessons with fremanezumab as the third CGRP antibody in our hospital: focus on factors predicting response

Restarting migraine preventive treatment with CGRP antibodies after drug holiday: Insights from Pavia real-world experience

Clinical impact of Rimegepant in acute migraine management for triptan non-responders

Switching anti-CGRP monoclonal antibodies benefits 25% of non-responders – an observational study of 82 cases

Evaluating the efficacy of monoclonal antibodies targeting CGRP in migraine treatment and the effect of combination therapy with Onabotulinum Toxin Type-A – a retrospective study

Characteristics of people with migraine using rimegepant in the Adelphi migraine Disease Specific Programme^TM (DSP)

Real-life experience of rimegepant in episodic migraine

Anti-CGRP antibodies in patients with migraine and autoimmune disease with concomitant immunosuppressants/immunomodulators treatment: interactions, safety and effectiveness

Response to eptinezumab in chronic cluster headache – a case report

Characteristics of patients prescribed rimegepant vs. all patients seeking migraine care via telemedicine

The effect of 9-months fremanezumab preventive treatment on the triptan response and on the incidence of triggers and prodromal symptoms in patients with HFEM

Multi-parametric efficacy assessment of Eptinezumab in patients with chronic migraine and medication overuse headache – early results from a third level headache center

Quarterly fremanezumab: assessing migraine relief and patient satisfaction

Refractory chronic migraine: no symptomatic relief after 20 preventive medications

Atogepant in clinical practice – the experience of a tertiary centre